Aculys Pharma Completes Patient Enrollment for Phase 3 Clinical Trial on Pitolisant in Patients with Narcolepsy

Tokyo, Japan, July 22, 2024 — Aculys Pharma, Inc. (“Aculys”), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announced that it has finished enrolling patients for the domestic Phase 3 clinical trial on the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy. Hidemasa Tanigaki, Chief Executive Officer of […]